{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:09:59Z","timestamp":1782025799257,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10072-013-1316-x","type":"journal-article","created":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T03:52:10Z","timestamp":1360209130000},"page":"831-839","source":"Crossref","is-referenced-by-count":27,"title":["Drug development status for Alzheimer\u2019s disease: present scenario"],"prefix":"10.1007","volume":"34","author":[{"given":"Shubham","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Medhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,8]]},"reference":[{"issue":"4","key":"1316_CR1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2174\/156720508785132299","volume":"5","author":"RE Becker","year":"2008","unstructured":"Becker RE, Greig NH (2008) Alzheimer\u00e2\u20ac\u2122s disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res 5(4):346","journal-title":"Curr Alzheimer Res"},{"issue":"R1","key":"1316_CR2","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1093\/hmg\/ddq142","volume":"19","author":"K Bettens","year":"2010","unstructured":"Bettens K, Sleegers K, Van Broeckhoven C (2010) Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19(R1):R4\u2013R11","journal-title":"Hum Mol Genet"},{"issue":"5","key":"1316_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/14728222.2011.557363","volume":"15","author":"K Chopra","year":"2011","unstructured":"Chopra K, Misra S, Kuhad A (2011) Neurobiological aspects of Alzheimer\u2019s disease. Expert OpinTher Targets 15(5):535\u2013555","journal-title":"Expert OpinTher Targets"},{"issue":"7","key":"1316_CR4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol 9(7):702\u2013716","journal-title":"Lancet Neurol"},{"issue":"4","key":"1316_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA (2010) 11C-PiB PET assessment of change in fibrillar amyloid-[beta] load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4):363\u2013372","journal-title":"Lancet Neurol"},{"key":"1316_CR6","unstructured":"Clinicaltrial.gov. ALADDIN study\u2014phase III: antigonadotropin-leuprolide in Alzheimer\u2019s disease drug INvestigation (VP-AD-301). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00231946?term=NCT00231946&rank=1"},{"key":"1316_CR7","unstructured":"Clinicaltrial.gov. effect of LY450139 on the long term progression of Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00594568?term=NCT00594568&rank=1"},{"key":"1316_CR8","unstructured":"Clinicaltrial.gov. a long-term safety and tolerability extension study of bapineuzumab in Alzheimer disease patients. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00998764?term=NCT00998764&rank=1"},{"key":"1316_CR9","unstructured":"Clinicaltrial.gov. effect of LY2062430 on the progression of Alzheimer\u2019s disease (EXPEDITION2). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00904683?term=NCT00904683&rank=1"},{"key":"1316_CR10","unstructured":"Clinicaltrial.gov. open-label treatment with MPC-7869 for patients with Alzheimer\u2019s who previously participated in an MPC-7869 protocol. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00380276?term=NCT00380276&rank=1"},{"key":"1316_CR11","unstructured":"Clinicaltrial.gov. a study of oral PF-01913539 in patients with mild to moderate Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01066481?term=NCT01066481&rank=1"},{"key":"1316_CR12","unstructured":"Clinicaltrial.gov. a phase II, Multicenter, double blind, placebo-controlled safety, tolerability study of BMS-708163 in patients with mild to moderate Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00810147?term=NCT00810147&rank=1"},{"key":"1316_CR13","unstructured":"Clinicaltrial.gov. a phase 2 study evaluating the efficacy and safety of PF 04494700 in mild to moderate Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00566397?term=NCT00566397&rank=1"},{"key":"1316_CR14","unstructured":"Clinicaltrial.gov. safety and cognitive function study of EVP-6124 in patients with schizophrenia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00968851?term=NCT00968851&rank=1"},{"key":"1316_CR15","unstructured":"Clinicaltrial.gov. multiple IV dose study of PF-04360365 in patients with mild to moderate Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00722046?term=NCT00722046&rank=1"},{"key":"1316_CR16","unstructured":"Clinicaltrial.gov. a study to determine the clinical safety\/tolerability and exploratory efficacy of EHT 0202 as adjunctive therapy to acetylcholinesterase inhibitor in mild to moderate Alzheimer\u2019s disease (EHT0202\/002). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00880412?term=NCT00880412&rank=1"},{"key":"1316_CR17","unstructured":"Clinicaltrial.gov. study of the safety & efficacy of GM-CSF (leukine) in the treatment of Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01409915?term=NCT01409915&rank=1"},{"key":"1316_CR18","unstructured":"Clinicaltrial.gov. a phase 2a study to evaluate the effect of rilapladib (SB-659032) in Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01428453?term=NCT01428453&rank=1"},{"key":"1316_CR19","unstructured":"Clinicaltrial.gov. a study to evaluate the efficacy and safety of MABT5102A in patients with mild to moderate Alzheimer\u2019s disease (ABBY). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01343966?term=NCT01343966&rank=1"},{"key":"1316_CR20","unstructured":"Clinicaltrial.gov. efficacy, safety and tolerability study of AVP-923 (dextromethorphan\/quinidine) for treatment of symptoms of agitation in Alzheimer\u2019s patients. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01584440?term=NCT01584440&rank=1"},{"key":"1316_CR21","unstructured":"Clinicaltrial.gov. a study of PRX-03140 in Subjects with Alzheimer\u2019s disease receiving a stable dose of donepezil. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00672945?term=NCT00672945&rank=1"},{"key":"1316_CR22","unstructured":"Clinicaltrial.gov. to evaluate effects of AZD1446, placebo and donepezil in patients with Alzheimer\u2019s disease. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01125683?term=NCT01125683&rank=1"},{"key":"1316_CR23","unstructured":"Clinicaltrial.gov. SGS742 in patients with mild to moderate Alzheimer\u2019s disease (AD). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00093951?term=NCT00093951&rank=1"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-013-1316-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-013-1316-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-013-1316-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T05:19:49Z","timestamp":1559107189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-013-1316-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,8]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1007\/s10072-013-1316-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,8]]}}}